Amlodipine labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Labels and Packages== | |||
PRINCIPAL DISPLAY PANEL - 5 mg Tablets | PRINCIPAL DISPLAY PANEL - 5 mg Tablets | ||
Revision as of 21:18, 12 March 2014
| Amlodipine |
|---|
| NORVASC®, AMLODIPINE®, AMLODIPINE BESYLATE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Amlodipine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Labels and Packages
PRINCIPAL DISPLAY PANEL - 5 mg Tablets
Norvasc® 5 mg*
Amlodipine Besylate
10 Tablets
 |
PRINCIPAL DISPLAY PANEL - 10 mg Tablets
Norvasc® 10 mg*
Amlodipine Besylate
10 Tablets
References
- ↑ "NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH]". Retrieved 6 March 2014.